Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Open accessThe DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductions concerning their effects and interactions and indicate which of the TCAs are the most useful. The relative toxicity of TCAs continues to be more precisely defined, as do TCA interactions with selective serotonin reuptake inhibitors (SSRIs). TCA interactions with monoamine oxidase inhibitors (MAOIs) have been, historically, an uncertain and difficult question, but are now well understood, although this is not reflected in the literature. The data indicate that nortriptyline and desipramine have the most pharmacologically desirable characteristics as noradrenaline reuptake inhibitors (NRIs), and as drugs with few interactions that are also safe when coadministered with either MAOIs or SSRIs. Clomipramine is the only available antidepressant drug that has good evidence of clinically relevant serotonin and noradrenaline reuptake inhibition (SNRI). These data assist drug selection for monotherapy and combination therapy and predict reliably how and why pharmacodynamic and pharmacokinetic interactions occur. In comparison, two newer drugs proposed to have SNRI properties, duloxetine and venlafaxine, may have insufficient NRI potency to be effective SNRIs. Combinations such as sertraline and nortriptyline may therefore offer advantages over drugs like venlafaxine that have fixed ratios of SRI/NRI effects that are not ideal. However, no TCA/SSRI combination is sufficiently safe to be universally applicable without expert knowledge. Standard texts (e.g. the British National Formulary) and treatment guidelines would benefit by taking account of these new data and understandings. British Journal of Pharmacology (2007) 151 , 737–748; doi: 10.1038/sj.bjp.0707253
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, different TCAs inhibit 5-HT and NE reuptake to varying degrees.”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [344]
In the citing paper
“For instance, amitriptyline, imipramine, and desipramine strongly inhibit 5-HT reuptake, 344”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [344]
Citations
Cites
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816 · cited 1×
“That result accords with a review covering 37 studies about sponsorship that showed a significant association between industry sponsorship and pro-industry conclusions (Bekelman et al., 2003).”
ResultIngelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003) · BMJ · doi:10.1136/bmj.326.7400.1171 · Cited by 635
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Smith, D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.396 · Cited by 538
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 3×
“The PET study of SERT binding from Meyer et al. (2004) demonstrates comparable SERT antagonism in human striatum (B80”
BackgroundInfluentialTherapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.
Schulz, M., & Schmoldt, A. (2003) · PubMed · Cited by 439
Sánchez, C., & Hyttel, J. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006986824213 · Cited by 429
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
Gillman, P. K. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei210 · Cited by 397
Self-citationBlockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
Bolden-Watson, C., & Richelson, E. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90194-8 · Cited by 390
Buckley, N. A., & McManus, P. R. (2002) · BMJ · doi:10.1136/bmj.325.7376.1332 · Cited by 380
Meta-analytical studies on new antidepressants
Anderson, I. M. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.161 · Cited by 351
Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.
Richelson, E., & Nelson, A. (1984) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21446-x · Cited by 341
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., & Schuetz, E. G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00006 · Cited by 316
Clinical Handbook of Psychotropic Drugs
(2015) · Hogrefe Publishing eBooks · doi:10.1027/00474-000 · Cited by 314
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302 · cited 2×
“venlafaxine only marginally attenuates the pressor response, even at the usual maximum dose of 375 mg day 1 (Harvey et al., 2000).”
Backgroundde Leon, J., Armstrong, S. C., & Cozza, K. L. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.1.75 · Cited by 300
Metabolism of Tricyclic Antidepressants
Rudorfer, M. V., & Potter, W. Z. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006949816036 · Cited by 296
Anderson, I. M. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+<1::aid-da1>3.3.co;2-j · Cited by 278
Tricyclic Antidepressant Poisoning: Cardiovascular Toxicity
Thanacoody, H. K. R., & Thomas, S. H. L. (2005) · Toxicological Reviews · doi:10.2165/00139709-200524030-00013 · Cited by 275
A history of antipsychotic drug development
Shen, W. W. (1999) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(99)90082-2 · Cited by 273
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 257
A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action
Gillman, P. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.016 · Cited by 248
Self-citationA comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs
Kongsamut, S., Kang, J., Chen, X.-L., Roehr, J., & Rampe, D. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02074-5 · Cited by 242
Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population
Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P., Steward, J. Q., McMunn, C., Ihrie, P., Mehall, J. M., Edwards, T. L., & Dawson, E. P. (2004) · Pharmacogenomics · doi:10.1517/14622416.5.7.895 · Cited by 236
PM Frequencies of Major CYPs in Asians and Caucasians
Mizutani, T. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120023681 · Cited by 234
Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg062 · Cited by 228
Moclobemide: Therapeutic Use and Clinical Studies
Bonnet, U. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00245.x · Cited by 227
Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death
Witchel, H. J., Hancox, J. C., & Nutt, D. J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00010 · Cited by 221
Evidence-based pharmacotherapy of obsessive–compulsive disorder
Fineberg, N. A., & Gale, T. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004675 · Cited by 211
Pharmacology of antidepressants
Richelson, E. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.5.511 · Cited by 203
Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data
Lawrence, K. R., Adra, M., & Gillman, P. K. (2006) · Clinical Infectious Diseases · doi:10.1086/503839 · Cited by 200
Self-citationDuloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers
Skinner, M. H., Kuan, H., Pan, A., Sathirakul, K., Knadler, M. P., Gonzales, C. R., Yeo, K. P., Reddy, S., Lim, M., Ayan‐Oshodi, M., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.28 · Cited by 195
Partial Response and Nonresponse to Antidepressant Therapy: Current Approaches and Treatment Options
Hirschfeld, R. M. A., Montgomery, S. A., Aguglia, E., Amore, M., Delgado, P. L., Gastpar, M., Hawley, C., Kasper, S., Linden, M., Massana, J., et al. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0913 · Cited by 193
Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor
Oates, J. A., & Sjoerdsma, A. (1960) · Neurology · doi:10.1212/wnl.10.12.1076 · Cited by 189
Nelson, J. C., Mazure, C. M., Jatlow, P. I., Bowers, M. B., & Price, L. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.007 · Cited by 189
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178
von Moltke, L. L., Greenblatt, D. J., Court, M. H., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199504000-00008 · Cited by 176
Millan, M. J., Gobert, A., Rivet, J. ‐., Adhumeau‐Auclair, A., Cussac, D., Newman‐Tancredi, A., Dekeyne, A., Nicolas, J. ‐., & Lejeune, F. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00982.x · Cited by 170
Serotonin syndrome: history and risk
Gillman, P. (1998) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1998.tb00976.x · Cited by 167
Self-citationDepression and sleep: pathophysiology and treatment
Thase, M. E. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/mthase · Cited by 166
Parkes, J. (1981) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.44.9.857 · Cited by 162
Differential physiological effects of a low dose and high doses of venlafaxine in major depression
Debonnel, G., Saint-André, É., Hébert, C., de Montigny, C., Lavoie, N., & Blier, P. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006413 · Cited by 148
Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo
Sharpley, A. L., Vassallo, C. M., & Cowen, P. J. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00273-5 · Cited by 141
Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder
Stein, D. J., Spadaccini, E., & Hollander, E. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503000-00002 · Cited by 136
Linezolid and Serotonergic Drug Interactions: A Retrospective Survey
Taylor, J. J., Wilson, J. W., & Estes, L. L. (2006) · Clinical Infectious Diseases · doi:10.1086/504809 · Cited by 136
Carlsson, A., & Lindqvist, M. (1969) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1969.tb08287.x · Cited by 135
Teschemacher, A. G., Seward, E. P., Hancox, J. C., et al. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702800 · Cited by 135
Westlind-Johnsson, A., HERMANN, R., Huennemeyer, A., Hauns, B., Lahu, G., Nassr, N., Zech, K., Ingelman‐Sundberg, M., & von Richter, O. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.015 · Cited by 128
Childhood adversity and vulnerability to mood and anxiety disorders
Young, E. A., Abelson, J. L., Curtis, G. C., & Nesse, R. M. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:2<66::aid-da2>3.0.co;2-3 · Cited by 118
Turcotte, J., Debonnel, G., de Montigny, C., Hébert, C., & Blier, P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00220-7 · Cited by 116
Australian and New Zealand clinical practice guidelines for the treatment of depression
(2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01377.x · Cited by 115
Mechanism of Sodium Channel Block by Venlafaxine in Guinea Pig Ventricular Myocytes
Khalifa, M., Daleau, P., & Turgeon, J. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35098-0 · Cited by 114
Nielsen, K. K., Flinois, J.-P., Beaune, P. H., & Brøsen, K. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13120-0 · Cited by 105
Richelson, E. (2003) · PubMed · Cited by 103
Vincent, S., Bieck, P. R., Garland, E. M., Loghin, C., Bymaster, F. P., Black, B. K., Gonzales, C., Potter, W. Z., & Robertson, D. (2004) · Circulation · doi:10.1161/01.cir.0000130847.18666.39 · Cited by 102
Pharmacological treatment for unipolar psychotic depression
Wijkstra, J., Lijmer, J. G., Balk, F. J., Geddes, J. R., & Nolen, W. A. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.010470 · Cited by 96
Chalon, S., Granier, L., Vandenhende, F., Bieck, P. R., Bymaster, F. P., Joliat, M. J., Hirth, C., & Potter, W. Z. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300209 · Cited by 95
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype
Jiang, Z., Dragin, N., Jorge-Nebert, L. F., Martin, M. V., Guengerich, F. P., Aklillu, E., Ingelman‐Sundberg, M., Hammons, G., Lyn‐Cook, B. D., Kadlubar, F. F., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000204994.99429.46 · Cited by 93
Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants
Brøsen, K. (2004) · Therapies · doi:10.2515/therapie:2004003 · Cited by 92
Yue, Q., Zhong, Z., Tybring, G., Dalén, P., Dahl, M., Bertilsson, L., & Sjöqvist, F. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90069-8 · Cited by 91
Christensen, M., Tybring, G., Mihara, K., Yasui‐Furokori, N., Carrillo, J. A., Ramos, S., Andersson, K., Dahl, M., & Bertilsson, L. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121788 · Cited by 90
Rossi, S. (2002) · Informa Healthcare eBooks · doi:10.3109/9780824706081.019 · Cited by 89
Blockade of the HERG human cardiac K+ channel by the antidepressant drug amitriptyline
Jo, S., Youm, J. B., Lee, C. O., et al. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703222 · Cited by 78
Biological basis of depression and therapeutic relevance.
Richelson, E. (1991) · PubMed · Cited by 76
Ghose, K., Coppen, A. J., & Turner, P. (1976) · Psychopharmacology · doi:10.1007/bf00427291 · Cited by 76
Major Depression and Mental Health Care Utilization in Canada: 1994 to 2000
Patten, S. B., & Beck, C. A. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900505 · Cited by 75
Vandel, S. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80088-3 · Cited by 75
Shin, J., Park, J. Y., Kim, M. J., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1102 · Cited by 70
Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles
Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman‐Sundberg, M., Härtung, T., & Coecke, S. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.04.001 · Cited by 67
Szegedi, A., Wetzel, H., Leal, M., Härtter, S., & Hiemke, C. (1996) · PubMed · Cited by 67
Drug‐Induced QT Interval Prolongation—Regulatory Guidance and Perspectives on hERG Channel Studies
Shah, R. R. (2005) · Novartis Foundation symposium · doi:10.1002/047002142x.ch19 · Cited by 66
Gillman, P. K. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.750 · Cited by 66
Self-citationSim, S. C., & Ingelman‐Sundberg, M. (2006) · Humana Press eBooks · doi:10.1385/1-59259-998-2:183 · Cited by 64
Assessing the Comparative Effectiveness of Antidepressant Therapies
Parker, G. B., Roy, K., Wilhelm, K. A., & Mitchell, P. B. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0209 · Cited by 64
Mann, K., Hiemke, C., Schmidt, L., & Bates, D. W. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000189897.16307.65 · Cited by 60
WILL AMITRIPTYLINE PREVENT THE "CHEESE" REACTION OF MONOAMINE-OXIDASE INHIBITORS?
Pare, C. M. B., Hallström, C., Kline, N. S., et al. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91030-3 · Cited by 60
Clinical Handbook of Psychotropic Drugs
(2017) · Hogrefe Publishing eBooks · doi:10.1027/00496-000 · Cited by 59
Preskorn, S. (2003) · Journal of Psychiatric Practice · doi:10.1097/00131746-200305000-00006 · Cited by 59
Blier, P., Saint-André, É., Hébert, C., de Montigny, C., Lavoie, N., & Debonnel, G. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006395 · Cited by 55
Who Will Challenge Evidence-Based Medicine?
Goodman, N. W. (1999) · Journal of the Royal College of Physicians of London · doi:10.1016/s0035-8819(25)01720-9 · Cited by 54
Antidepressant drugs for narcolepsy
Vignatelli, L., D’Alessandro, R., & Candelise, L. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003724.pub3 · Cited by 54
Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala, M., Coppa, F., Cappucciati, C., Brambilla, P., d'Allio, G., Caverzasi, E., Barale, F., & Ferrari, G. M. D. (2006) · PubMed · Cited by 53
Preskorn, S. (2003) · Journal of Psychiatric Practice · doi:10.1097/00131746-200303000-00006 · Cited by 47
The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects
Jiang, Z., Shu, Y., Chen, X., Huang, S., Zhu, R., Wang, W., He, N., & Zhou, H. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0445-6 · Cited by 46
Buckley, N. A., & McManus, P. R. (1998) · Drug Safety · doi:10.2165/00002018-199818050-00006 · Cited by 45
Differential blockade of neuronal voltage-gated Na+ and K+ channels by antidepressant drugs
Nicholson, G. M., Blanche, T., Mansfield, K. J., & Tran, Y. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02239-2 · Cited by 45
Therapeutic Monitoring of Psychotropic Drugs
Baumann, P., Hiemke, C., Ulrich, S., Gaertner, I., Rao, M. L., Eckermann, G., Gerlach, M., Kuss, H., Laux, G., Müller-Oerlinghausen, B., et al. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00014 · Cited by 43
Doggrell, S. A., & Woodruff, G. N. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb08393.x · Cited by 41
Lopez-Munoz, F. J., Álamo, C., Rubio, G., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00165-9 · Cited by 40
Effect of venlafaxine on imipramine metabolism
Albers, L. J., Reist, C., Vu, R., et al. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00213-4 · Cited by 39
Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics
Furman, K. D., Grimm, D. R., Mueller, T., Holley-Shanks, R. R., Bertz, R., Williams, L. A., Spear, B. B., & Katz, D. A. (2004) · Pharmacogenetics · doi:10.1097/00008571-200405000-00002 · Cited by 38
Nelson, J. C., Portera, L., & Leon, A. C. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.030 · Cited by 37
Leucht, S., Hackl, H., Steimer, W., et al. (2000) · Psychopharmacology · doi:10.1007/s002130050006 · Cited by 35
Excess Fatality From Desipramine in Children and Adolescents
Amitai, Y., & Frischer, H. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000184931.26176.4a · Cited by 32
Linezolid and Serotonin Toxicity
Gillman, P. K. (2003) · Clinical Infectious Diseases · doi:10.1086/378895 · Cited by 31
Self-citationEvidence-based pharmacotherapy for obsessive–compulsive disorder
Fineberg, N. A. (1999) · Advances in Psychiatric Treatment · doi:10.1192/apt.5.5.357 · Cited by 30
Sola, C. L., Bostwick, J. M., Hart, D. A., & Lineberry, T. W. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.3.330 · Cited by 30
Fatal toxicity associated with antidepressant use in primary care
Mason, J. M., Freemantle, N., & Eccles, M. (2000) · Europe PMC (PubMed Central) · doi:10.25405/ncl.34661673 · Cited by 28
Pronounced Differences in the Disposition of Clomipramine Between Japanese and Swedish Patients
Shimoda, K., Jerling, M., Böttiger, Y., et al. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00002 · Cited by 28
Gruetter, C. A., Lemke, S. M., Anestis, D. K., et al. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90827-q · Cited by 27
Coppen, A. J., Ghose, K., Swade, C., et al. (1978) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1978.tb04569.x · Cited by 26
DeBattista, C., Sofuoglu, M., & Schatzberg, A. F. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00161-9 · Cited by 24
New drugs, old problems: Revisiting… Pharmacological management of treatment-resistant depression
Cowen, P. J. (2005) · Advances in Psychiatric Treatment · doi:10.1192/apt.11.1.19 · Cited by 24
Cutler, N. R. (1978) · JAMA · doi:10.1001/jama.1978.03290210046023 · Cited by 21
Hyttel, J. (1990) · Springer eBooks · doi:10.1007/978-94-009-1912-9_59 · Cited by 20
Smith, R. (2001) · PubMed · Cited by 20
Co‐prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?
McManus, P. R., Mant, A., Mitchell, P. B., et al. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01319.x · Cited by 19
Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach.
Preskorn, S. H. (1986) · PubMed · Cited by 19
Dual Action Antidepressants and Some Important Considerations
Gupta, R. K., Tiller, J. W. G., & Burrows, G. D. (2003) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2003.01169.x · Cited by 18
Who Will Challenge Evidence-Based Medicine?
Goodman, N. W. (2000) · Clinical Risk · doi:10.1177/135626220000600603 · Cited by 17
Antidepressant drugs for narcolepsy
Vignatelli, L., D’Alessandro, R., & Candelise, L. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003724.pub2 · Cited by 17
Danie, W. A., Syrek, M., Ryłko, Z., et al. (2002) · PubMed · Cited by 16
Excess Fatality from Desipramine and Dosage Recommendations
Amitai, Y., & Frischer, H. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200410000-00002 · Cited by 15
Gillman, K., & Whyte, I. M. (2004) · Oxford University Press eBooks · doi:10.1093/med/9780198527480.003.0003 · Cited by 15
Fatal intoxication due to dothiepin
Keller, T., Schneider, A., & Tutsch-Bauer, E. (2000) · Forensic Science International · doi:10.1016/s0379-0738(99)00234-0 · Cited by 14
Bassetti, C. L. (1999) · Current Treatment Options in Neurology · doi:10.1007/s11940-999-0019-3 · Cited by 14
Doxepin inhibits CYP2D6 activity in vivo.
Szewczuk-Bogusławska, M., Kiejna, A., Beszłej, J. A., et al. (2005) · PubMed · Cited by 11
Reboxetine prevents the tranylcypromine-induced increase in tyramine levels in rat heart
Dostert, P., Castelli, M. G., Cicioni, P., et al. (1994) · Springer eBooks · doi:10.1007/978-3-7091-9324-2_21 · Cited by 11
Seppälä, T. T., Linnoila, M., Soundergaard, I., et al. (1981) · PubMed · Cited by 11
Comment on: Serotonin syndrome due to co-administration of linezolid and venlafaxine
Gillman, P. K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh404 · Cited by 10
Self-citationRegulation of Clinical Research Sponsored by Pharmaceutical Companies: A Proposal
Sotelo, J. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030306 · Cited by 10
Drug interactions and fluoxetine: a commentary from a clinician’s perspective
Gillman, P. K. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.965 · Cited by 5
Self-citationRelative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers
Ullmann, U., Lehnfeld, R., Bliesath, H., et al. (2009) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp39271 · Cited by 4
Bioavailability Investigation of Two Different Oral Formulations of Doxepin
Geister, U., Gaupp, M., Arnold, P., et al. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300024 · Cited by 4
Successful physostigmine treatment of acute dothiepin intoxication.
Schulz, M., & Schmoldt, A. (1994) · PubMed · Cited by 2
PII-63The effect of duloxetine, escitalopram, and sertraline on CYP 2D6 function
Preskorn, S., BAKER, B., Klick-Davis, A., et al. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.188 · Cited by 1
Research works printed but not linked: 6
- 10.1002/(SICI)1520-6394(1997)5:2<84::AID-DA4>3.0.CO;2-5 · DOI
- 10.1002/(SICI)1520-6394(1998)7:1 <11::AID-DA4>3.0.CO;2-I · doi:10.1002/(sici)1520-6394(1998)7:1
- Brunton LL, 2006, Goodman and Gilman's The Pharmacologicl Basis of Therapeutics
- Dawson AH, 2004, Med Toxicol, 851
- Preskorn S, 2006, 2006 guide to psychiatric drug interactions, Primary Psychiatry, 13, 35
- Whyte IM, 2004, Med Toxicol, 843
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“…SNRIs can all inhibit the reuptake of 5-HT by SERTs, specially SSRIs have the selective inhibition on SERTs, which increase the concentration of 5-HT in the synaptic gap and play antidepressive roles by effecting on 5-HTRs in postsynaptic membrane, 343,344 which also activate the cAMP-PKA pathway.”
BackgroundAGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“, 2014); TCA (Anderson, 2000; Cohn et al., 1996; Danish University Antidepressant Group, 1986; Danish University Antidepressant Group, 1990; Danish University Antidepressant Group, 1993; Doogan and Langdon, 1994; Fabre et al., 1996; Feighner and Boyer, 1989; Furukawa et al., 2009; Gillman, 2007; Guaiana et al., 2007;…”
BackgroundSLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Metadata
- Authors
- Gillman, P. K.
- Affiliations
- PsychoTropical Research (AU)
- Corresponding author
- Gillman, P K
- ORCID
- Gillman, P K
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-07
- Volume
- 151
- Issue
- 6
- Pages
- 737-748
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2014120
- OpenAlex
- W2155964805
- Cited by
- 694
- References
- 132
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 51 · 2023: 43 · 2022: 60 · 2021: 52 · 2020: 43 · 2019: 36 · 2018: 39 · 2017: 42 · 2016: 35 · 2015: 27 · 2014: 30 · 2013: 31 · 2012: 37
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- tricyclic antidepressants, drug interactions, cytochrome P450 inhibition, nortriptyline, desipramine, clomipramine, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, norepinephrine reuptake inhibition, duloxetine, venlafaxine, sertraline, combination therapy
- MeSH terms
- Animals, Antidepressive Agents, Tricyclic, Central Nervous System, Cytochrome P-450 Enzyme System, Drug Interactions, Drug Therapy, Combination, Humans, Monoamine Oxidase Inhibitors, Selective Serotonin Reuptake Inhibitors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.